Literature DB >> 25342274

Rate and timing of spontaneous resolution in a vitreomacular traction group: should the role of watchful waiting be re-evaluated as an alternative to ocriplasmin therapy?

Spyridon Dimopoulos1, Karl-Ulrich Bartz-Schmidt1, Faik Gelisken1, Kai Januschowski1, Focke Ziemssen1.   

Abstract

INTRODUCTION: The incidence of spontaneous resolution of vitreomacular traction (VMT) is low in studies of Ocriplasmin that have had a limited follow-up. Previous studies did not look for morphological parameters in the natural history using spectral-domain ocular coherence tomography (SD-OCT) imaging. The purpose of this study was to investigate how often and when spontaneous VMT resolution occurs in candidates for Ocriplasmin therapy.
METHODS: The study is a retrospective chart review of patients who would have high chances of a benefit by an Ocriplasmin injection, without epiretinal membrane or vitreomacular adhesion of 1500 µm or more on SD-OCT. Main outcome measures were the frequency of complete VMT resolution and the best corrected visual acuity seen in the natural history.
RESULTS: Out of the 46 patients that were included after screening 889 SD-OCT images, 20 were found to exhibit spontaneous resolution during the follow-up period (median: 594 days, 95% CI 567 to 719 days), the majority after 6-12 months of observation (95% CI 266 to 617 days). The group with spontaneous VMT resolution and a mean improvement of one line in best corrected visual acuity included a few patients losing vision by macular hole formation. In the absence of resolution, patients lost on average one early treatment diabetic retinopathy study letter per year. Younger age was found to increase the chance of spontaneous resolution.
CONCLUSIONS: A shorter follow-up might underestimate the incidence of spontaneous VMT resolution as the functional outcome of watchful waiting. The likelihood of resolution does not seem to decrease after 12 months. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Macula; Retina; Vitreous

Mesh:

Substances:

Year:  2014        PMID: 25342274     DOI: 10.1136/bjophthalmol-2014-304961

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  14 in total

1.  Knowledge of vitreomacular traction (VMT) scenarios: Is doing nothing still a beneficial alternative and, if so, when?

Authors:  Focke Ziemssen; Karl Ulrich Bartz-Schmidt; Spyros Dimopoulos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-18       Impact factor: 3.117

2.  Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.

Authors:  Sleiman Abou Ltaif; Luke Herbert
Journal:  BMJ Case Rep       Date:  2015-09-10

3.  Comparison of the horizontal diameter to a modeled area of traction in eyes with vitreomacular traction: is the diameter close enough to the truth?

Authors:  Christoph Paul; P Krug; H H Müller; J Wachtlin; S Mennel; S Müller; S Schmitz-Valckenberg; T Bertelmann; R G Schumann
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-28       Impact factor: 3.117

4.  [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].

Authors:  M Maier; S Abraham; C Frank; N Feucht; C P Lohmann
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

Review 5.  [Watchful waiting as a therapeutic principle for diseases of the vitreoretinal interface].

Authors:  H Hoerauf; B Kirchhof
Journal:  Ophthalmologe       Date:  2017-11       Impact factor: 1.059

Review 6.  Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.

Authors:  Irini Chatziralli; George Theodossiadis; Paraskevi Xanthopoulou; Michael Miligkos; Sobha Sivaprasad; Panagiotis Theodossiadis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-30       Impact factor: 3.117

7.  A retrospective cohort study in patients with tractional diseases of the vitreomacular interface (ReCoVit).

Authors:  Peter Stalmans
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-02-22       Impact factor: 3.117

8.  Functional improvement assessed by multifocal electroretinogram after Ocriplasmin treatment for vitreomacular traction.

Authors:  Settimio Rossi; Francesco Testa; Paolo Melillo; Ada Orrico; Michele Della Corte; Francesca Simonelli
Journal:  BMC Ophthalmol       Date:  2016-07-18       Impact factor: 2.209

9.  PNEUMATIC VITREOLYSIS FOR RELIEF OF VITREOMACULAR TRACTION.

Authors:  Clement K Chan; Jason N Crosson; Calvin E Mein; Noha Daher
Journal:  Retina       Date:  2017-10       Impact factor: 4.256

Review 10.  Pneumatic Vitreolysis for Management of Symptomatic Focal Vitreomacular Traction.

Authors:  Clement K Chan; Calvin E Mein; Jason N Crosson
Journal:  J Ophthalmic Vis Res       Date:  2017 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.